株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Elidel(アトピー性皮膚炎):予測と市場分析

ELIDEL (Atopic Dermatitis) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 292829
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
Elidel(アトピー性皮膚炎):予測と市場分析 ELIDEL (Atopic Dermatitis) - Forecast and Market Analysis to 2022
出版日: 2013年11月30日 ページ情報: 英文 49 Pages
概要

当レポートでは、免疫抑制作用のあるカルシニューリン阻害剤、MedaのElidel(ピメクロリムス)について調査分析し、アトピー性皮膚炎の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測、売上情報などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状

第4章 疾病の管理

  • 診断
  • 治療の概要

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 Elidel

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

目次
Product Code: GDHC295DFR

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

Meda's Elidel contains the molecule pimecrolimus and akin to Astellas' Protopic belongs to the ascomycin class of macrolactam immunosuppressives. The exact mechanism by which Elidel exerts its effect in atopic dermatitis is still unknown (Elidel prescribing information, 2011). However, studies have found that Elidel binds with high affinity to macrophilin-12 (also referred to as 12 kDa FK506-binding protein or FKBP-12) and inhibits the calcium-dependent protein phosphatase, calcineurin. Calcineurin in turn inhibits T cell activation by blocking the transcription of early cytokines.

Scope

  • Overview of Atopic Dermatitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Elidel including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Elidel for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Elidel performance
  • Obtain sales forecast for Elidel from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
  • 4.2. Treatment Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Elidel

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Atopic Dermatitis Patients
    • 7.4.2. Percent Drug-treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Author
    • 7.7.2. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Atopic Dermatitis
  • Table 2: Treatment Guidelines for Atopic Dermatitis
  • Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013
  • Table 4: Leading Treatments for Atopic Dermatitis, 2013
  • Table 5: Product Profile - Elidel
  • Table 6: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies
  • Table 7: Elidel SWOT Analysis, 2013
  • Table 8: Global Sales Forecasts ($m) for Elidel, 2012-2022
  • Table 9: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin
  • Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis
Back to Top